Villaescusa BR, Arce HAA, Merlín LJC, Guerreiro HAM, Leyva RA, Lam DRM, Hernández RP

Language: Spanish
References: 10
Page: 354-358
PDF size: 67.76 Kb.

ABSTRACT

Introduction: Chronic myeloid leukemia (CML) is characterized by an excessive production of myeloid cells and their progenitors. Cytoskeletal structural disorders of erythrocytes have been demonstrated with the formation of band 3 aggregates on its surface that have been linked with the anemia that occurs in these patients.
Objective: To evaluate the involvement of natural anti-band 3 antibodies in the erythrocyte removal from circulation and its possible relation with anemia.
Method: A follow up study was performed in 16 patients with CML in different clinical stages in which the levels of natural anti band 3 antibodies were determined by an enzyme immunoassay. Blood hemoglobin levels were determined using an automatic analyzer Mindray 3200.
Results: Significant low levels (p ‹ 0.01) of natural band 3 antibodies and hemoglobin were demonstrated in patients samples in chronic phase compared with results obtained during the hematological remission phase were both parameters maintained within normal levels.
Conclusion: The results suggest the possible involvement of natural anti band 3 antibodies in the premature removal of erythrocytes that could explain the anemia observed in patients in the chronic phase of the disease.

REFERENCES

1. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol. 2014;165:273-86.

2. Druker BJ, Marin D. Chronic myelogenous leukemia. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita. Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 10th ed. Filadelfia, Pa: Lippincott Williams & Wilkins; 2015.p.1644-53.

3. Perrotti D. Where are we going with CML research? Leukemia Supplements. 2012;1:S51-S53; doi:10.1038/leusup.2012.26

4. Carella A, Branford S, Deininger M. What challenges remain in chronic myeloid leukemia research? Editorials and Perspectives. Haematologica. 2013;98(8):1168-72.

5. Kottahachchi DU, Ariyaratne TR, Jayasekera GAU. Mass spectrometry based analysis of erythrocyte membrane associated proteins in chronic myeloid leukemia patients in Sri Lanka. International Letters of Chemistry, Physics and Astronomy. 2014;19(1):74-86.

6. Arce AA, Villaescusa R. Organización de la membrana celular: banda 3, estructura y function. Rev Cubana Hematol Inmunol Hemoter. 2005 [citado 2015 Abr 23];21( 3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892005000300001&lng=es .

7. Arese P, Turrini F, Schwarzer E. Band 3/complement-mediated recognition and removal of normally senescent and pathological human erythrocytes. Cellular Physiol Biochem. 2005;16(4):133-46.

8. Arce AA, Villaescusa R, Merlín JC. Ensayo inmunoenzimático para la determinación de anticuerpos naturales anti banda 3. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2008 Dic [citado 2015 Abr 23];24(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892008000300006&lng=es .

9. Das AK, Sinha AK, Basu J. Erythrophagocytosis and its relation to band 3 clustering in chronic myelogenous leukaemia. IUBMB Life 2008;41:539-45.

10. Govekar R, Kawle P, Thomas R, Advani S, Zingde S. Eryptotic Phenotype in Chronic Myeloid Leukemia: Contribution of Neutrophilic Cathepsin G. Anemia. 2012; 2012: Article ID 659303, 7 pages. doi:10.1155/2012/659303.